Breaking News

BAP Pharma Opens US Headquarters in Landing, NJ

February 2, 2016

Marks the first US location for clinical trials materials supplier

BAP Pharma, a UK-based specialist supplier of comparators for clinical trials, has opened its new U.S. headquarters in Landing, NJ. The new headquarters is the company’s first location in the U.S.

BAP Pharma manages the clinical trial supply process including sourcing, delivery and customized solutions to its clients, which include some of the UK’s top pharmaceutical companies. The decision to expand its operations to New Jersey was made in response to the company’s rapid growth, according to founder and managing director, Bashir Parkar. Pharmaceutical industry veteran Lucas Nigro will manage the U.S. headquarters.

“Since 2011, BAP Pharma has been establishing itself as a global leader in the clinical trial supply sector based on attention to quality and best-in-class client service,” said Mr. Parkar. “The opening of our U.S. headquarters in New Jersey is an important milestone for our company and will enhance our ability to provide fast, seamless service to our clients.”

The new HQ is equipped with state-of-the-art, fully enclosed temperature controlled ambient and cold room storage facilities.

“The facility and location proved a perfect fit for our company,” said Mr. Parkar. “Its proximity to a significant number of global pharmaceutical and biotechnology companies, including our current clients, made it particularly attractive. New Jersey’s excellent transportation network also enhances our ability to deliver products quickly and efficiently throughout the region and around the world.”

Related Contract Manufacturing:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research